Skip to main content
Fig. 5 | Cost Effectiveness and Resource Allocation

Fig. 5

From: An ex-ante cost-utility analysis of the deemed consent legislation compared to expressed consent for kidney transplantations in Nova Scotia

Fig. 5

The sensitivity of ICUR to changes in dialysis and maintenance immunosuppressant drug costs for a 1% increase in deceased donor kidney transplantations. ICUR incremental cost-utility ratio, QALY quality-adjusted life-year, WTP willingness to pay, KT kidney transplantation, HD hemodialysis, PD peritoneal dialysis EV expected value

Back to article page